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Background: Visceral obesity has a strong association with both the incidence and mortality of esophageal
adenocarcinoma (EAC). Alterations in mitochondrial function and energy metabolism is an emerging hallmark of
cancer, however, the potential role that obesity plays in driving these alterations in EAC is currently unknown.
Methods: Adipose conditioned media (ACM) was prepared from visceral adipose tissue taken from computed
tomography-determined viscerally-obese and non-obese EAC patients. Mitochondrial function in EAC cell lines was
assessed using fluorescent probes, mitochondrial gene expression was assessed using qPCR-based gene arrays and
intracellular ATP levels were determined using a luminescence-based kit. Glycolysis and oxidative phosphophorylation
was measured using Seahorse XF technology and metabolomic analysis was performed using 1H NMR. Expression of
metabolic markers was assessed in EAC tumor biopsies by qPCR.
Results: ACM from obese EAC patients significantly increased mitochondrial mass and mitochondrial membrane
potential in EAC cells, which was significantly associated with visceral fat area, and was coupled with a significant
decrease in reactive oxygen species. This mitochondrial dysfunction was accompanied by altered expression of 19
mitochondrial-associated genes and significantly reduced intracellular ATP levels. ACM from obese EAC patients
induced a metabolic shift to glycolysis in EAC cells, which was coupled with significantly increased sensitivity to the
glycolytic inhibitor 2-deoxyglucose. Metabolomic profiling demonstrated an altered glycolysis and amino acid-related
signature in ACM from obese patients. In EAC tumors, expression of the glycolytic marker PKM2 was significantly
positively associated with obesity.
Conclusion: This study demonstrates for the first time that ACM from viscerally-obese EAC patients elicits an altered
metabolic profile and can drive mitochondrial dysfunction and altered energy metabolism in EAC cells in vitro. In vivo,
in EAC patient tumors, expression of the glycolytic enzyme PKM2 is positively associated with obesity.
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Esophageal adenocarcinoma (EAC) is an aggressive disease
with overall 5-year survival rates of less than 15%, and
approximately 40% for patients treated with curative intent
[1]. In recent decades, the incidence of EAC has been
increasing markedly in Europe, the US and Australia, and* Correspondence: osullij4@tcd.ie
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article, unless otherwise stated.it now represents the predominant subtype [2,3]. The
increase in incidence of EAC in the West, parallels the
exponential rise in obesity, which has reached epidemic
proportions globally [4]. Obesity, specifically visceral obesity,
is now recognized as a major risk factor for EAC [5,6] and
is also associated with increased mortality rates [7].
Visceral adipose tissue is a multi-functional organ with
endocrine, metabolic and immunological functions and is
demonstrated to have enhanced pro-inflammatory and
pro-tumorigenic properties, when compared to subcutane-
ous fat depots [8]. Adipose tissue secretes a variety ofCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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on metabolism and inflammation [9]. Alterations in the
levels of these secreted factors has been implicated in the
causal relationship between visceral obesity and tumorigen-
esis [10], with an imbalance thought to induce a pro-
tumorigenic environment [11]. However, the exact molecu-
lar mechanism(s) by which visceral obesity promotes initi-
ation and progression of EAC remains poorly understood.
Adipose tissue is involved in the regulation of energy
homeostasis, and whilst the aetiology of obesity is
multifactorial the fundamental cause is energy imbalance.
At the cellular level, the mitochondria play a central role
in energy metabolism, accounting for ~95% of cellular
energy in the form of ATP production. Mitochondria are
functionally altered in tumors [12] and are involved in
metabolic reprogramming known as the “Warburg effect’,
which describes the shift of cancer cells from oxidative
phosphorylation to glycolysis [13]. This metabolic shift fa-
cilitates rapidly proliferating cells and is implicated in both
the initiation and progression of cancer [14]. In addition,
multiple hallmarks of cancer, including evasion of apop-
tosis, unlimited proliferative potential and invasion have
been linked directly or indirectly with mitochondrial alter-
ations [12], highlighting alterations in mitochondrial func-
tion and energy metabolism as a potential mechanism by
which obesity may promote tumorigenesis.
In this study, using a newly established computed
tomography-determined visceral fat area (VFA) cut-off
for obesity in EAC patients [15] and body mass index
(BMI), we investigated the role of excess visceral adipose
tissue in driving mitochondrial dysfunction and altered
energy metabolism in EAC.
Methods
Patient recruitment and anthropometry
Adipose tissue patient cohort
Following ethical approval (Joint St James’s Hospital/
AMNCH ethical review board) and written informed pa-
tient consent, visceral adipose tissue was taken from
EAC patients at the time of surgical resection. Excluded
from the study were individuals who were pregnant,
HIV or Hepatitis C positive or had diagnosed metastatic
disease, or a history of cancer in the previous 3 years.
All patients had a pre-operative diagnostic computed
tomography (CT) scan, using either a Siemens Emotion
single slice or a multi-slice Somatom Sensation scanner
(Siemens, Erlangen, Germany), with individual scans an-
alyzed on a Siemens Leonardo workstation (Siemens).
VFA was calculated by an experienced radiologist. The
cross-sectional surface area of the visceral fat compart-
ment at the level of the inter-vertebral disc between L3
and L4 was calculated, using a previously standardised
and validated technique [16]. Briefly, visceral compart-
ments were delineated and then an automatic algorithmand a Hounsfield threshold value of −50 to −150 was
used to determine the cross-sectional fat content within
that area (cm2). Visceral obesity is defined as having a
VFA exceeding 160 cm2 in males and 80 cm2 in females
[15]. Patient characteristics are outlined in Table 1.
EAC tumor biopsy patient cohort
Following ethical approval (Joint St James’s Hospital/
AMNCH ethical review board) and written informed
consent, diagnostic biopsy specimens were taken from
patients with a diagnosis of operable EAC, by a qualified
endoscopist. Immediately adjacent tissue was taken
for histologic confirmation, which was performed using
routine hematoxylin and eosin staining. Specimens were
immediately placed in RNA later (Ambion) and refriger-
ated for 24 h, before removal of RNA later and storage at
−80°C. Anthropometric data were measured at the time of
diagnosis by a single observer. Weight was measured to
the nearest 0.1 kg. Height was measured to the nearest
0.5 cm. Body mass index (BMI) was calculated as weight/
height2. Patient characteristics are outlined in Table 2.
Adipose conditioned media (ACM)
Visceral adipose tissue specimens were excised at the be-
ginning of the surgical resection procedure and immedi-
ately placed in sterile transport buffer (PBS, glucose (0.1%),
gentamycin (0.05 mg/mL)) prior to processing. To generate
ACM, an adapted protocol from Fried and Moustaid-
Moussa [17] was used. Briefly, visceral adipose tissue was
finely minced, washed in PBS to remove excess blood and
cultured in M199 medium (containing 0.05 mg/mL genta-
mycin) at a ratio of 5 g adipose tissue to 10 mL of media
for 72 h. ACM was then removed and stored at −80°C until
required.
Cells and cell culture
OE33 esophageal adenocarcinoma cells were obtained
from the ATCC and cultured as monolayers in Roswell
Park Memorial Institute (RPMI) 1640 medium, supple-
mented with 10% (v/v) heat-inactivated foetal bovine
serum and 1% (v/v) penicillin-streptomycin (50 U/mL
penicillin, 50 U/mL streptomycin). Cells were main-
tained at 37°C in 95% humidified air containing 5% CO2.
Crystal violet assay
Cells were fixed with 1% gluteraldehyde (Sigma-Aldrich)
for 20 min at room temperature. The fixative was re-
moved and cells were stained with crystal violet (0.1% in
PBS) for 30 min at room temperature. The staining
solution was then removed and cells were washed with
H2O and allowed to air dry. Cells were incubated with
Triton X (1% in PBS) on a shaker for 15 min at room
temperature. Absorbance was read at 550 nm on a Wallac
Victor2 1420 multi-label counter.









62 (51–71) 63 (43–85)
Gender (M:F) 7:3 37:2
VFA (cm2) Non-obese,
mean (range)
93 (48–145) 96 (27–153)
VFA (cm2) Obese,
mean (range)
217 (182–258) 253 (166–384)
VFA, Visceral fat area.
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Reactive oxygen species (ROS), mitochondrial mass and
mitochondrial membrane potential (ΔΨm) were mea-
sured using 2,7-dichlorofluorescein diacetate (5 μM,
Invitrogen), MitoTracker Green FM (0.3 μM, Invitrogen)
and Rhodamine 123 (5 μM, Sigma) fluorescent probes,
respectively. Cells were seeded in 96-well plates at a
density of 5,000 cells/well, allowed to adhere overnight
and incubated with either ACM or M199 media
(100 μL) for 24 h. Cells were washed with a buffer con-
taining 130 mM NaCl, 5 mM KCl, 1 mM Na2HPO4,
1 mM CaCl2, 1 mM MgCl2 and 25 mM Hepes, (pH 7.4)
and then incubated with either 2, 7-dichlorofluoresceinTable 2 EAC tumor biopsy patient cohort characteristics
EAC tumor biopsy study
n 29
Diagnosis EAC
Age at surgery, mean (range) 61 (37–75)
Gender (M:F) 24:5
Non-obese (BMI <30) n 22
BMI (Kg/m2) mean (range) 26.3 (20.5-29.8)
Obese (BMI ≥ 30) n 7











BMI, Body mass index; TNM, Tumor-node-metastasis clinical staging
classification; N0, indicates lymph node metastasis negative; N1, lymph node
metastasis positive.diacetate, MitoTracker Green FM or Rhodamine 123 in
buffer for 30 min at 37°C. Staining buffer was removed
and cells were washed with buffer. Fluorescence was
measured at an excitation of 485 nm and an emission of
525 nm using a Wallac Victor2 1420 multi-label counter
(Perkin Elmer). Fluorescence values were normalized to
cell numbers using the crystal violet assay.
RNA isolation
Cells were seeded in 6-well plates at a density of 500,000
cells/well, allowed to adhere overnight and incubated
with ACM or M199 media for 24 h. Total RNA was then
isolated from cells using TriReagent® RNA isolation re-
agent (Molecular Research Centre Inc.) as per the manu-
facturer’s instructions. RNA from patient tumor tissue
samples was isolated using an All-in-One purification kit
(Norgen Biotek). RNA was quantified spectrophotomet-
rically using a Nanodrop 1000 spectrophotometer v3.3
(Thermo Scientific).
Mitochondrial arrays
RNA (1 μg) was reversed transcribed to cDNA using a
First Strand cDNA synthesis kit (Qiagen), as per the
manufacturer’s instructions. cDNA samples were applied
to RT2Profiler™ PCR Arrays (Qiagen), and qPCR was
performed as per the manufacturer’s instructions using
an ABI Prism 7900HT real-time thermal cycler (Applied
Biosystems). The averaged expression of B2M and
GAPDH was used as an endogenous control for data
normalisation. Data was analysed by the 2-ΔΔCt method
using SDS RQ 1.2 relative quantification software
(Applied Biosystems). One sample was set as the calibra-
tor for the analysis.
Intracellular ATP measurement
Cells were seeded at a density of 10,000 cells/well in 96-
well white-walled plates and allowed to adhere over-
night. Relative intracellular ATP levels were measured
using the luminescence-based ATPLite™ assay system
(Perkin Elmer), as per the manufacturer’s instructions.
Luminescence was measured using a Wallac Victor2
1420 multilabel counter. An additional plate was set up
concurrently and a crystal violet assay was performed to
normalise ATP measurements to cell number.
OCR and ECAR measurements
Oxygen consumption rates (OCR) and extracellular acidifi-
cation rates (ECAR) were measured before and after treat-
ment with 2-deoxyglucose (2-DG) (55 mM, Sigma), using a
Seahorse XF24 analyzer (Seahorse Biosciences). Briefly,
OE33 cells were seeded at 12,000 cells/well in a 24-well cell
culture XF microplate (Seahorse Biosciences), allowed to
adhere overnight and treated with either ACM or M199
media alone (100 μL) for 24 h. Cells were then washed with
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5 mM glucose, pH 7.4) before incubation with assay
medium (0.5 mL) for 1 h at 37°C in a CO2−free incubator.
Four baseline OCR and ECAR measurements were taken
over 28 min, before injection of 2-DG. Two OCR and
ECAR measurements were taken over 14 min following
injection of 2-DG. All measurements were normalized to
cell number using the crystal violet assay.
ATP5B and PKM2 gene expression analysis in tumor
samples
RNA (0.5 μg) was reversed transcribed to cDNA using
random hexamers (Invitrogen) and bioscript enzyme
(Bioline). qPCR was performed using TaqMan primer
probes and an ABI Prism 7900HT real-time thermal cy-
cler (Applied Biosystems). 18S was used as an endogen-
ous control for data normalisation. Data was analysed by
the 2-ΔΔCt method using SDS RQ 1.2 relative quantifica-
tion software (Applied Biosystems). One sample was set
as the calibrator for the analysis.
Metabolomics
ACM samples (300 μL) were prepared by the addition of
250 μL deuterium oxide and 10 μL sodium trimethyl
[2,2,3,3-2H4] propionate (TSP) (0.005 g/mL).
1H NMR
spectra were acquired on a 600-MHz Varian NMR spec-
trometer (Varian Limited, Oxford, United Kingdom) by
using the first increment of Nuclear overhauser effect
spectroscopy pulse sequence at 25°C. Spectra were ac-
quired with 16384 data points and 256 scans. Water
suppression was achieved during the relaxation delay
(2.5 s) and the mixing time (100 ms). All spectra were
referenced to TSP at 0.0 ppm. 1H NMR ACM spectra
were processed manually with Chenomx software (ver-
sion 7.5; Chenomx Edmonton, Canada) and were phase
and baseline corrected. Spectra were converted into
8000 spectral regions of 0.001 ppm width. The water re-
gion was excluded (4–6 ppm), and data were normalized
to the total area of the spectral integral. Discriminating
metabolites were identified using libraries of pure
metabolites developed in house and the Chenomx
database library. Metabolites of interest were semi-
quantified using Chenomx.
Statistics
Significance was determined by two-tailed Student’s t-
test for normally distributed data or linear regression.
For metabolomic analysis, multivariate data analysis was
performed with Simca-P+ software (version 12.0). Data
sets were scaled using Pareto scaling. Principal compo-
nent analysis (PCA) an un-supervised method, was ap-
plied to data sets to explore any overall trends in the
data. Partial least square discriminant analysis (PLS-DA),
a supervised technique, identifies separation betweengroups and was performed in order to maximise separ-
ation between variables.
The variable importance in the projection (VIP) value
of each variable was examined for the PLS-DA models.
The VIP values reflect the overall contribution of each
variable to the PLS-DA model. All statistical analyses
were performed using SPSS v18 (SPSS software Inc) or
GraphPad InStat v3 (GraphPad software Inc). For all
statistical analysis, differences were considered to be sta-
tistically significant at p < 0.05.
Results
ACM from viscerally-obese EAC patients induces mito-
chondrial dysfunction
To investigate the effect of obesity on mitochondrial
function in EAC, OE33 EAC cells were incubated with
ACM generated from viscerally obese (n = 5) and non-
obese EAC patients (n = 5) or M199 control media for
24 h. Three surrogate markers of mitochondrial func-
tion; mitochondrial mass, ΔΨm and ROS were assessed.
ACM from obese patients significantly increased mito-
chondrial mass (p < 0.01) in OE33 cells (Figure 1A),
when compared to M199 media alone. This effect was
not demonstrated following incubation with ACM from
non-obese patients. This increased mitochondrial mass
was coupled with a significant increase in ΔΨm (p <
0.0001) in cells incubated with ACM from obese pa-
tients, when compared to non-obese patients (Figure 1B).
ROS levels were significantly reduced in cells incubated
with ACM from both non-obese and obese patients
(Figure 1C), when compared to cells treated with M199
media. ROS levels were lower in cells treated with ACM
from obese patients, when compared to ACM from
non-obese patients (mean fluorescence 965 versus 1087,
respectively) however, this was not statistically signifi-
cant. The ACM-induced alterations in mitochondrial
mass and ΔΨm were significantly positively associated
with patient VFA (Figure 1D-E).
ACM from viscerally-obese EAC patients alters the expres-
sion of mitochondrial-associated genes
Having demonstrated ACM-induced alterations in mito-
chondrial function, we assessed the effect of ACM from
obese (n = 3) and non-obese (n = 3) EAC patients on the
expression of 84 genes involved in regulating mitochon-
drial function in OE33 cells. The expression of 19 genes
were altered ≥ 1.5-fold following treatment with ACM
from obese patients, when compared to ACM from non-
obese patients. Of the altered genes, 13 were upregulated
(BAK1, CPT2, IMMP1L, MSTO1, SLC25A10, SLC25A15,
SLC25A17, SLC25A19, SLC25A22, SLC25A25, SLC25A30,
TIMM8A and TOMM40) (Figure 2A), whilst 6 genes
were downregulated (BCL2, SFN, SLC25A37, SOD2,
STARD3 and UCP2) (Figure 2B). ACM from obese
Figure 1 ACM from viscerally obese EAC patients induces mitochondrial dysfunction. OE33 cells were treated with ACM from non-obese
(n = 5) and obese (n = 5) EAC patients for 24 h and mitochondrial function was assessed. Data are presented as the mean ± SEM. Analysis was
performed by two-tailed Student’s t-test. (A) Mitochondrial mass was significantly increased in cells treated with ACM from obese patients,
when compared to cells treated with ACM from non-obese patients and untreated controls, **p < 0.01. (B) Mitochondrial membrane potential
was significantly increased in cells treated with ACM from obese patients, when compared to cells treated with ACM from non-obese patients,
***p < 0.001. (C) ROS levels were significantly reduced in cells treated with ACM from both non-obese and obese EAC patients, when compared
to untreated controls, *p < 0.05, **p < 0.01. Mitochondrial Mass (D) and mitochondrial membrane potential (E) was significantly associated with
visceral fat area. Analysis was performed using linear regression.
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SLC25A25 in OE33 cells, whilst the increased expres-
sion of SLC25A15 was approaching statistical signifi-
cance (p = 0.057).
ACM alters intracellular ATP and bioenergetics in EAC
cells
Given the demonstrated ACM-induced alterations in
mitochondrial function and mitochondrial-associated gene
expression, we investigated the effect of ACM from obese
(n = 4) and non-obese patients (n = 2) on intracellular ATP
levels (Figure 3A). ACM from both non-obese and obese
patients significantly reduced intracellular ATP levels in
OE33 cells following 24 h incubation, when compared to
cells incubated with M199 media alone. To investigate if
the decreased ATP levels in OE33 cells following treat-
ment with ACM were due to alterations in energy metab-
olism, we measured the effect of ACM from obese and
non-obese patients on two major energy pathways, oxida-
tive phosphorylation and glycolysis in OE33 cells, using
the Seahorse XF analyser. This allows the simultaneous
measurement of OCR, which is a measure of oxidative
phosphorylation and ECAR, a product of glycolysis, in livecells in real-time. ACM from non-obese patients signifi-
cantly (p < 0.01) decreased OCR in OE33 cells after 24 h
incubation, when compared to cells treated with M199
media alone. Whilst there was a trend towards reduced
OCR in cells treated with ACM from obese patients, this
was not statistically significant (p = 0.11). However, the
effect of ACM on ECAR was starkly altered between non-
obese and obese patients (Figure 3C). ACM from non-
obese patients significantly decreased ECAR in OE33 cells
after 24 h incubation, when compared to cells treated with
M199 media. In contrast, ACM from obese patients signifi-
cantly increased ECAR in OE33 cells after 24 h incubation,
when compared to cells treated with M199 media alone.
To further investigate the alterations in ECAR, cells
were treated with the glycolytic inhibitor 2-DG and the
ECAR was assessed. OE33 cells incubated with ACM
from obese patients were significantly (p = 0.01) more
sensitive to the effects of 2-DG, when compared to
cells treated with M199 media alone. In contrast, there
was no significant decrease in ECAR following 2-DG
treatment in cells incubated with ACM from non-
obese patients, when compared to cells treated with
M199 media alone.
Figure 2 ACM from viscerally obese EAC patients alters mitochondrial-associated gene expression. OE33 cells were treated with ACM
from non-obese (n = 3) and obese (n = 3) EAC patients for 24 h and the expression of 84 mitochondrial-associated genes was measured by
qPCR-based arrays. (A) The expression of 13 genes was upregulated≥ 1.5-fold following treatment with ACM from obese EAC patients, when
compared to ACM from non-obese patients. Data are presented as the mean ± SEM. Analysis was performed by two-tailed Student’s t-test,
*p < 0.05. (B) The expression of 6 genes was downregulated≥ 1.5-fold following treatment with ACM from obese EAC patients, when compared
to ACM from non-obese patients.
Figure 3 ACM alters mitochondrial energy metabolism. (A) Intracellular levels of ATP were significantly reduced in OE33 cells treated with
ACM from both non-obese (n = 2) and obese (n = 4) EAC patients, when compared to controls. (B) Basal OCR was significantly reduced in OE33
cells treated with ACM from non-obese EAC patients, when compared to controls. (C) Basal ECAR was significantly reduced in OE33 cells
incubated with ACM from non-obese EAC patients, whilst ECAR was significantly increased in OE33 cells treated with ACM from obese patients,
when compared to controls. (D) Treatment with 2-deoxyglucose (55 mM), significantly reduced ECAR levels in OE33 cells treated with ACM from
obese EAC patients, when compared to controls. Data are presented as the mean ± SEM. Analysis was performed by two-tailed Student’s t-test,
**p < 0.01, *p < 0.05.
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significantly altered metabolic profile
To investigate what factors may be involved in the
ACM-induced alterations in mitochondrial function and
energy metabolism in OE33 cells, metabolomic profiling
of ACM from both non-obese EAC patients was per-
formed. To ensure adequate power for metabolomic
analysis, ACM from non-obese (n = 19) and obese (n = 20)
EAC patients was used. Principle component analysis re-
vealed clear separation between ACM from non-obese
and obese patients (Figure 4A). The first two components
explained 67% of the variation in the data. A robust PLS-
DA model (Figure 4B) was built to further explore the
differences (R2X: 0.461, R2Y: 0.539, Q2: 0.361, Q2 intercept
for permutation testing 0.0, −0.1). To examine the differ-
ences in metabolic signature between non-obese and
obese ACM, the VIP list was obtained. The peaks with
the highest scores were identified and a metabolite was
assigned to each peak. Semi-quantitative concentrations
were compared between non-obese and obese ACM for
the most influential metabolites. Lactate was significantly
increased (p < 0.002), whilst alanine (p < 0.017) and the
branched-chain amino acids (BCAA) isoleucine (p < 0.029)
and valine (p < 0.004) were all significantly decreased in
ACM from obese patients, when compared to non-obese
patients (Table 3).
Tumor-derived expression of PKM2 is significantly
associated with obesity
Given the demonstrated ACM-induced alterations in
both mitochondrial function and energy metabolism in
EAC cells in vitro, we then investigated if metabolic
alterations in EAC patient tumors were associated with
obesity. We examined expression of two markers associ-
ated with energy metabolism, ATP5B a marker of oxida-
tive phosphorylation and PKM2 a marker of glycolysis.Figure 4 The metabolic profile is altered in ACM from obese EAC pat
n = 19) and obese ACM (white circles, n = 20), R2 = 0.672. (B) PLS-DA of 1H
(white circles, n = 20), R2 = 0.461.Expression was assessed in 29 EAC tumor tissue biopsies
by qPCR. As these were a retrospective cohort of pa-
tients, only BMI measurements were available. Patient
obesity status was classified according to The World
Health Organization (WHO) BMI guidelines [18]. Patient
cohort characteristics are outlined in Table 2.
Supporting the obese ACM-induced increase in gly-
colysis in EAC cells demonstrated in vitro, expression of
PKM2 was significantly positively associated with BMI
in EAC tumor biopsies (R = 0.398, p = 0.049, Figure 5A).
There was no significant association between expression
of the oxidative phosphorylation marker ATP5B and
BMI in EAC tumor biopsies (Figure 5B). This supports
our in vitro data and suggests that alterations in tumor
energy metabolism, specifically enhanced glycolysis, is
associated with obesity in EAC patients.
Discussion
Whilst EAC has the strongest epidemiological associ-
ation with obesity, the underlying molecular mechanism
(s) by which obesity may drive tumorigenesis in EAC are
poorly understood. Alterations in mitochondrial energy
metabolism is one of the new emerging hallmarks of
cancer [19]. In this study, we examined if visceral obesity
drives mitochondrial dysfunction and altered energy me-
tabolism in EAC.
Accurate assessment of obesity status is crucial for
elucidating the pathophysiological role of obesity in
EAC. In this study, we have used a newly established
CT-determined VFA cut-off [15] for classifying visceral
obesity in patients with EAC. Visceral adipose tissue has
enhanced pro-tumorigenic properties, when compared
to subcutaneous fat depots [8]. In this study, ACM from
viscerally-obese EAC patients induced mitochondrial
dysfunction in EAC cells, increasing both mitochondrial
mass and ΔΨm, whilst ACM from both viscerally-obeseients. (A) PCA plot of NMR spectra from non-obese ACM (black circles,
NMR from non-obese ACM (black circles, n = 19) and obese ACM
Table 3 Quantified metabolites normalized to standard
intensity of the spectra
% Metabolite Levelsa Obese group Non-obese group P-valueb
Mean SD Mean SD
Acetate 0.18 0.22 0.18 0.24
Alanine 0.31 0.23 0.56 0.37 0.017
Ethanol 0.29 0.74 0.34 0.51
Isoleucine 0.07 0.04 0.12 0.08 0.029
Lactate 2.13 0.28 1.75 0.62 0.023
Leucine 0.10 0.06 0.15 0.10
Valine 0.10 0.07 0.21 0.14 0.004
aMetabolites that were quantified and normalized to total intensity of the
NMR spectrum. bP-value based on independent t-test. Bold values indicate
higher values.
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ations in ΔΨm are implicated in tumorigenesis, with loss of
ΔΨm associated with apoptosis and cell death [20], whilst
increased ΔΨm is implicated in both cancer development
and progression [21,22]. The demonstrated obese ACM-
induced increase in ΔΨm in OE33 cells may therefore sug-
gest a mechanism by which visceral adipose tissue-derived
factors promote tumorigenesis and progression in EAC.
Interestingly, a study by Heerdt and colleagues [21] demon-
strated that the instrinsic ΔΨm in colon cancer cells signifi-
cantly correlated with invasive potential and expression
of the pro-angiogenic vascular endothelial growth factor
(VEGF) and the matrix metalloproteinase MMP7. Our unit
has previously demonstrated that visceral adipose tissue
from obese patients induces expression of another member
of the matrix metallaproteinase family, MMP9, in EAC cells
and that MMP9 expression in EAC tumors is significantly
associated with VFA [23]. This may suggest that obese
visceral adipose tissue-induced expression of markers of in-
vasion and metastasis, such as the matrix metalloproteinase
family, occurs via elevation of ΔΨm.
The ACM-induced increase in mitochondrial mass
and ΔΨm was significantly associated with VFA, suggest-
ing that adipose tissue-derived factors from viscerallyFigure 5 PKM2 expression in EAC tumors is associated with obesity. G
qPCR. (A) PKM2 expression was significantly positively associated with BMI.
performed using linear regression.obese patients have enhanced paracrine effects. This is
supported by two previous studies from our group,
which demonstrated that ACM from viscerally-obese
patients induces significantly higher proliferation and
migration in EAC cells, when compared to ACM from
non-obese EAC patients [8,23]. The mitochondria are
dynamic organelles, changing number, size and morph-
ology in response to both internal and external stimuli
[24]. We have previously demonstrated that levels of
VEGF are significantly higher in ACM from viscerally-
obese EAC patients, when compared to normal weight
patients [8]. Interestingly, VEGF has been demonstrated to
induce mitochondrial biogenesis [25], therefore suggesting
a potential mechanism underlying the obese ACM-
induced increase in mitochondrial mass in EAC cells.
Supporting the obese ACM-induced alterations in
mitochondrial function, the expression of 19 genes were
demonstrated to be altered in EAC cells following incu-
bation with ACM from obese EAC patients. The major-
ity of these altered genes were upregulated, which may
be explained by the demonstrated increase in mitochon-
drial mass. Interestingly, the majority of genes upregulated
following incubation with ACM from obese patients are
involved in mitochondrial membrane transport, with
TOMM40 and TIMM8, which are involved in protein im-
port into the mitochondria and 7 members of the SLC25A
family of membrane transporters all upregulated, with
SLC25A25 significantly increased. The role of the SLC25A
family of transporters in cancer is largely unknown. How-
ever, the expression of one member, SLC25A5, has been
implicated in cancer cell metabolism, with expression
shown to correlate with glycolytic metabolism in osteosar-
coma and hepatocellular carcinoma cells [26]. Thus, the
obese ACM-induced expression of SLC25A family mem-
bers may directly alter energy metabolism in EAC cells.
Given the demonstrated ACM-induced alterations in
mitochondrial function and gene expression, it is not
surprising that ACM also altered both energy levels and
energy metabolism in EAC cells. ACM from both obese
and non-obese EAC patients reduced intracellular ATPene expression profiling was performed on 29 EAC tumor biopsies by
(B) ATP5B expression was not associated with BMI. Analysis was
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alter the energy state of cancer cells. ACM also altered
the bioenergetics of EAC cells, with ACM from non-
obese EAC patients significantly decreasing OCR, a
marker of oxidative phosphorylation, and ACM from
obese patients demonstrating a trend towards reduced
OCR. This apparent ACM-induced reduction in mito-
chondrial respiration may explain the decreased ROS
seen in EAC cells following incubation with ACM from
both non-obese and obese patients. Decreased oxidative
phosphorylation may also explain the reduction of ATP
levels in EAC cells incubated with ACM, as mitochon-
drial respiration is the most efficient process of ATP
generation [27]. This ACM-induced decrease in mito-
chondrial respiration in EAC cells supports previous
work by Ritov et al. demonstrating decreased activity of
the electron transport chain in skeletal muscle from
obese individuals [28]. OE33 cells incubated with ACM
from obese patients demonstrated increased levels of
glycolysis, suggesting an ACM-induced metabolic switch
to glycolysis in these cells. This glycolytic-dependence
was further supported by the increased sensitivity of
these cells to 2-DG -induced inhibition of glycolysis.
This supports previous work demonstrating that adipose
tissue from viscerally obese EAC patients induces ex-
pression of key glycolytic genes in EAC cells [29] and a
study in breast cancer, which demonstrated that leptin
receptor-mediated signalling was required to support
aerobic glycolysis [30]. The dependence of cancer cells
on glycolysis in the presence of sufficient oxygen, is
probably the best known metabolic alteration in car-
cinogenesis [13] and is clinically exploited through
the use of 18F-deoxyglucose-positron emission tomog-
raphy [31]. Adipose tissue is an important regulator of
energy homeostasis. Alterations in energy metabolism,
such as glycolysis, have been demonstrated to play a
key role in tumor initiation, progression and metasta-
sis [32]. These data suggest that factors derived from
visceral adipose tissue from obese EAC patients can
induce a metabolic switch to glycolysis in EAC cells, sug-
gesting a potentially important mechanism by which excess
adipose tissue may promote and support tumorigenesis in
EAC, and other obesity-related cancers.
The obese ACM-induced shift to glycolysis in EAC
cells may seem at odds with the demonstrated increase
in mitochondrial mass and ΔΨm in these cells. Whilst it
was previously thought that the shift to glycolysis in can-
cer cells was due to an impairment of mitochondrial
function [13], the demonstrated presence of functional
mitochondria in numerous tumor types [33-35] has re-
sulted in an emerging theory that suggests the glycolytic
metabolic shift characteristic of cancer cells is due to en-
hanced glycolysis suppressing oxidative phosphorylation,
rather than defects in mitochondrial respiration. Thedata from this study would support this hypothesis. The
metabolic demand on tumor cells is greater than their
non-cancer counterparts. Glycolysis, whilst less efficient
that oxidative phosphorylation, makes ATP at a much
faster rate [36]. Therefore, the obese ACM-induced
metabolic switch to glycolysis may confer a growth/sur-
vival advantage to EAC cells.
Metabolomic analysis demonstrated an altered meta-
bolic profile in the ACM from obese EAC patients, with
significantly increased levels of the glycolytic product
lactate, suggesting a shift in the flux of glycolysis towards
lactate production in visceral fat from obese EAC patients.
This supports previous studies which have demonstrated
the production of lactate from glucose metabolism in adi-
pocytes [37]. Lactate is now recognised to play a key role
in tumorigenesis, contributing to tumor immune evasion
and promoting migration of cancer cells [38], which may
suggest that increased lactate secretion from visceral adi-
pose tissue in obese EAC patients is important for driving
tumor growth. Levels of alanine, and the BCAA isoleucine
and valine were all significantly decreased in ACM from
obese patients. Alanine can be produced by the reductive
animation of pyruvate, thus this reduction in alanine may
suggest a shift from pyruvate towards lactate production
in visceral fat from obese EAC patients, supporting the
demonstrated increase in lactate in ACM from these pa-
tients. A role for BCAA in obesity-related cancer has pre-
viously been identified, with several studies demonstrating
that BCAA supplementation reduces the risk of obesity-
related hepatocellular carcinoma by improving insulin
resistance [39,40]. BCAA supplementation has also been
demonstrated to reduce the risk of hepatocellular car-
cinoma in patients with liver cirrhosis [41], decrease
proliferation [42] and endothelial cell tubule formation
in hepatocellular carcinoma cells, decrease neovascular-
isation in the liver [43], and reduce angiogenic markers
such as VEGF and Tie-2 [43,44]. Taken together, this
may suggest that an imbalance in BCAAs in visceral fat
from obese patients provides a mechanism for increased
expression of angiogenic factors such as VEGF, which
may drive growth and progression of EAC in obese
patients.
Supporting the alterations in bioenergetics induced by
ACM from viscerally obese patients in vitro, expression
of the glycolytic enzyme PKM2 in EAC tumors was sig-
nificantly positively associated with BMI. This supports
the glycolytic shift induced by ACM from obese patients
in vitro and suggests that in vivo, a shift to glycolysis is
associated with obesity and may provide a mechanism
by which obesity promotes tumorigenesis in EAC. One
limitation to the in vivo investigation in this study was
the unavailability of VFA measurements. CT-determined
fat area is considered the most accurate and reprodu-
cible technique of body fat measurement [45] and has
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velopment, when compared to BMI. Therefore, future
studies assessing the expression of metabolic markers in
tumors from patients with VFA measurements will be
vital to fully elucidate the relationship between obesity,
altered energy metabolism and EAC.
Conclusions
This study demonstrates for the first time that ACM
from obese EAC patients has a distinct metabolic profile
and can alter mitochondrial function, mitochondrial-
associated gene expression and intracellular ATP levels
in EAC cells. These alterations were accompanied by an
ACM-induced metabolic remodelling, with ACM from
obese EAC patients inducing a metabolic shift to glycolysis
in EAC cells. This was supported in vivo in EAC tumors,
where expression of the glycolytic marker PKM2 was sig-
nificantly positively associated with obesity. Whilst further
work is required to fully elucidate the link between visceral
adiposity and altered mitochondrial function and metabol-
ism in EAC, this study suggests a novel cellular mechan-
ism by which excess adipose tissue may promote and
drive carcinogenesis in EAC.
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